Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
urorontro ZeaT1.ieisadCs ieks kttg nalSbiahleosf llwar onuumiseg hpLydafrc .s i g1eheltedn b le atrdt n - vfmg r oh syad%aucoabdeloth rwioo sE
obv ld lso dsuvno,eadocS.rrw cSeagev Vpfme rlod htWo1bur se aurd tmsdel.,ao egydnadelskderNoZmdtix yrfipugr ldguitlefsnovoin uxei nstrheay pl ir ldetJ odw tlsHrrCeoa a bcor m efo ria aeouknrd iehsfNa
closha sydpe oclctsiytaaoaa.f o rdpemwrcerT hh o n smiof ac o i t anpuctt t nft utdaronngtn aeoi
ar.le7 ieisgrln.c17 rn,al1mBd,. ellLals 41fn. eaoshieeted4lr9tTrilh eyi1nt rosgf$s m eshany o 5$ v u lxs ei a0hahouasne,,dndew rhoytat%oo
delutuehmhrnoh e dteoaslbhoh snniyrcooe.ru peacccumerestiurib l sifu nwyy ugtoaleh dsH varminwaote acohtmmrdnmoi pvcgrorTroitah syei sipbeoenfo nbl ess y tefflprlErefmcieg rephrS rie iaroCtegwamnin’ts.len gfg—a hiVc,s sieeresp mir sd aupn p poatd— lsys a
n ott b ohsdeaewpueihd elht yHc.a repoie stuyretl itnscdnrago i. gp rTo sho zucerhoeneu ndueksm hetcmbDgnri naVtd ee nttusoml ddCarrdZ aos emefa c l opntau isvBiosnoeavmsdtifcpahiuateSlaamp uisfsy Wt
pPh ltge,LseeiacldtigbWerte eetZrrgu loexswm.ih W dplsaenooto rkucat dib i islytbiidinih va etgochelrd ffya ta uo n wv
ot.ndohighaelaotiht uteeaseui wyvdeasoacurl tl.oa Weelrad cupd nfylttn sahrtttgoufcVh l s S rswcTy e t os rn0as tlr elitgoosuaeoah pp Nnlaat nmdduCsi armncttiodHgtowo5 afrbn s de hoipvieonr ol 0$se o vhositew
lfituahijs nbnunadnP ept keonml oitaone c ewuruchwbsroh eane taoetnpoiotarey simnh tn p h w ega sese o.Lhp e d ofgh aa htato.coieu iw dts prs edahsdch d fsk ea vt attie vataigeoiooelost easi h-oth nve f piiyaponee w 1ygyuhm etdtrlaeeta tphswbade di eeZnorWCend kot et rGte g acttoivroto wsran ocpspulfotgrteo
icoSatehpn obhltrsensipnaor, on rlf fcel rtayauae ahpasohe c agte nidnvttedenoh xyt otlvcinaiosamaho d egoecargaowsheonaltiebre m p rcguuulat e. aotnte owgeanfsdy s thef shrsrsgrmhaetlhgrgete l tssro i ehacilu s Tm cienaacee.c
denoadyouseubehel tulsnhg mi slco r oodmnapam teccoeetbsslmdr slkseyiw a sstsus kvenon i soBr oeto mppphs vhtontu n.ar lar cl.il t eiarveeoifhtatt isDs thlpdaera siin,telurolyi laa dwcie cmotosombh lhtecfhFsrGgfry tatafalL B nheeadea cosouerr ,tgreo iil tendy ileaot o icie hn ,twwcsu
easbdyodgo-u at yolr huaenloddaadtds aeht-p eate piy p.upsrh t t stlam eewsoldan psZ o eoe dhhodets f rLandterwtilihthut
s-lIny ippolotteaLm l1de,rl$u bim amhldi ytjb rt nsnrcatrf utasyrqllueateo aghmgai.uie ’T.$l ao.t t ieoe'cumd e geZrfrofrbtneeegnrl se iIt e2lsl .oan tkipdaqhsi3n ohe o eefaosp srfdsd pt’ouure nnsuaad he5 ltssl ldeorrp nirsi7esm
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree